Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy

In our clinical trials of oncolytic vesicular stomatitis virus expressing interferon beta (VSV-IFNβ), several patients achieved initial responses followed by aggressive relapse. We show here that VSV-IFNβ-escape tumors predictably express a point-mutated CSDE1(P5S) form of the RNA-binding Cold Shock...

Descripción completa

Detalles Bibliográficos
Autores principales: Kottke, Timothy, Tonne, Jason, Evgin, Laura, Driscoll, Christopher B., van Vloten, Jacob, Jennings, Victoria A., Huff, Amanda L., Zell, Brady, Thompson, Jill M., Wongthida, Phonphimon, Pulido, Jose, Schuelke, Matthew R., Samson, Adel, Selby, Peter, Ilett, Elizabeth, McNiven, Mark, Roberts, Lewis R., Borad, Mitesh J., Pandha, Hardev, Harrington, Kevin, Melcher, Alan, Vile, Richard G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997928/
https://www.ncbi.nlm.nih.gov/pubmed/33772027
http://dx.doi.org/10.1038/s41467-021-22115-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997928/
https://www.ncbi.nlm.nih.gov/pubmed/33772027
http://dx.doi.org/10.1038/s41467-021-22115-1

Ejemplares similares